Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
24.90
Dollar change
+0.59
Percentage change
2.43
%
IndexRUT P/E- EPS (ttm)-2.81 Insider Own0.69% Shs Outstand11.45M Perf Week6.78%
Market Cap286.10M Forward P/E- EPS next Y-1.28 Insider Trans7.09% Shs Float11.41M Perf Month24.69%
Income-32.17M PEG- EPS next Q-0.36 Inst Own67.27% Short Float2.57% Perf Quarter68.24%
Sales4.41M P/S64.88 EPS this Y-3.54% Inst Trans0.92% Short Ratio10.56 Perf Half Y71.13%
Book/sh9.23 P/B2.70 EPS next Y37.32% ROA-19.76% Short Interest0.29M Perf Year14.96%
Cash/sh2.93 P/C8.49 EPS next 5Y19.00% ROE-22.60% 52W Range13.48 - 25.37 Perf YTD34.59%
Dividend Est.- P/FCF- EPS past 5Y- ROI-30.36% 52W High-1.85% Beta0.57
Dividend TTM- Quick Ratio3.34 Sales past 5Y63.07% Gross Margin79.32% 52W Low84.72% ATR (14)1.38
Dividend Ex-Date- Current Ratio3.34 EPS Y/Y TTM-420.06% Oper. Margin-508.21% RSI (14)63.88 Volatility5.52% 6.33%
Employees13 Debt/Eq0.00 Sales Y/Y TTM-89.10% Profit Margin-729.31% Recom2.00 Target Price74.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-23.72% Payout- Rel Volume1.46 Prev Close24.31
Sales Surprise-29.96% EPS Surprise-25.00% Sales Q/Q84.04% EarningsNov 07 BMO Avg Volume27.74K Price24.90
SMA2013.08% SMA5020.49% SMA20042.30% Trades Volume40,398 Change2.43%
Date Action Analyst Rating Change Price Target Change
Sep-07-21Downgrade Wedbush Outperform → Neutral $22
Jun-29-21Initiated Aegis Capital Buy $60
Jan-19-21Reiterated H.C. Wainwright Buy $30 → $56
Jan-18-18Reiterated H.C. Wainwright Buy $38 → $49
Oct-17-17Resumed H.C. Wainwright Buy $38
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Mar-11-16Reiterated Wedbush Outperform $6 → $3
Jul-23-15Downgrade Jefferies Buy → Hold
Feb-28-24 07:30AM
Feb-16-24 08:00AM
Jan-18-24 08:30AM
Jan-11-24 04:05PM
Jan-08-24 07:30AM
07:30AM Loading…
Jan-02-24 07:30AM
Dec-20-23 07:30AM
Dec-19-23 07:30AM
Nov-07-23 07:50AM
07:30AM
Oct-31-23 07:30AM
Sep-25-23 07:30AM
Sep-06-23 07:30AM
Aug-31-23 10:43PM
Aug-13-23 10:07AM
08:21AM Loading…
Aug-08-23 08:21AM
07:30AM
Jun-23-23 06:14PM
Jun-22-23 07:30AM
Jun-20-23 07:30AM
May-16-23 09:29AM
May-09-23 07:53AM
07:30AM
Apr-26-23 07:30AM
Mar-30-23 07:30AM
Mar-21-23 07:30AM
Mar-10-23 05:36AM
Mar-09-23 07:50AM
07:30AM
Mar-06-23 08:28AM
07:30AM Loading…
Feb-28-23 07:30AM
Jan-06-23 07:00PM
Jan-04-23 07:30AM
Dec-22-22 07:30AM
Dec-07-22 07:44AM
Nov-22-22 07:01AM
Nov-06-22 09:24AM
Nov-03-22 09:05AM
07:30AM
Sep-27-22 08:30AM
Sep-21-22 07:30AM
Sep-07-22 07:30AM
Sep-01-22 06:20AM
Aug-11-22 06:22AM
Aug-04-22 10:45AM
07:30AM
Jun-30-22 07:33AM
Jun-20-22 07:30AM
Jun-02-22 01:00AM
May-30-22 07:06AM
May-17-22 04:05PM
May-07-22 08:27AM
May-05-22 08:55AM
07:30AM
May-03-22 08:15AM
Apr-20-22 08:24AM
Mar-21-22 07:30AM
Mar-15-22 06:21AM
Mar-10-22 09:43AM
07:30AM
Mar-08-22 07:30AM
Mar-01-22 07:30AM
Feb-17-22 07:30AM
Jan-21-22 10:21AM
Dec-23-21 07:30AM
Dec-21-21 07:30AM
Dec-16-21 07:30AM
Nov-22-21 11:46AM
Nov-15-21 06:01AM
Nov-04-21 10:15AM
07:40AM
07:30AM
Oct-28-21 03:06PM
Oct-27-21 04:50AM
Oct-14-21 06:57AM
Oct-08-21 03:35AM
Sep-22-21 07:30AM
Sep-21-21 12:33PM
Sep-20-21 07:30AM
Sep-13-21 07:30AM
Sep-07-21 01:49PM
Aug-10-21 04:35PM
Aug-05-21 08:45AM
07:30AM
Jul-29-21 03:05PM
Jul-28-21 07:30AM
Jul-15-21 06:38AM
04:17AM
04:00AM
Jun-23-21 03:16PM
Jun-21-21 07:30AM
Jun-08-21 10:38AM
May-21-21 08:00AM
May-06-21 09:15AM
07:30AM
May-03-21 07:30AM
Apr-15-21 09:05AM
Apr-12-21 07:30AM
Apr-06-21 07:02PM
Apr-05-21 04:05PM
XOMA Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sitko BradleyChief Investment OfficerOct 03Buy13.892503,4725,600Oct 04 04:30 PM
Sitko BradleyChief Investment OfficerOct 02Buy14.251,50021,3755,350Oct 04 04:30 PM
Hughes OwenExec Chairman and Interim CEOOct 02Buy13.831,00013,8303,500Oct 04 04:30 PM
Hughes OwenExec Chairman and Interim CEOSep 26Buy14.432,49936,0612,500Sep 27 04:30 PM
Hughes OwenExec Chairman and Interim CEOSep 25Buy14.651151Sep 27 04:30 PM
Sitko BradleyChief Investment OfficerMay 31Buy17.131,50025,7003,500Jun 02 04:30 PM
Hughes OwenInterim CEOMay 24Buy23.791,03224,5512,000May 25 04:30 PM
Hughes OwenInterim CEOMay 23Buy23.4696822,706968May 25 04:30 PM
Sitko BradleyChief Investment OfficerMay 23Buy19.0085016,1503,850May 25 04:30 PM
Sitko BradleyChief Investment OfficerMay 19Buy19.501,00019,5003,000May 22 04:30 PM
Sitko BradleyChief Investment OfficerMay 16Buy23.2050011,6022,000May 17 05:20 PM
Sitko BradleyChief Investment OfficerMay 15Buy23.401,50035,1001,500May 16 04:13 PM
Sitko BradleyChief Investment OfficerMay 12Buy18.992,00037,9852,000May 16 04:13 PM